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Abstract
Background: Bipolar disorder is a chronic and often debilitating illness. Current treatment options (both pharmaco- and 
psychotherapy) have shown efficacy, but for many leave a shortfall in recovery. Advances in the understanding of the 
pathophysiology of bipolar disorder suggest that interventions that target mitochondrial dysfunction may provide a 
therapeutic benefit.
Methods: This review explores the current and growing theoretical rationale as well as existing preclinical and clinical data 
for those therapies aiming to target the mitochondrion in bipolar disorder. A  Clinicaltrials.gov and ANZCTR search was 
conducted for complete and ongoing trials on mitochondrial agents used in psychiatric disorders. A PubMed search was also 
conducted for literature published between January 1981 and July 2017. Systematic reviews, randomized controlled trials, 
observational studies, case series, and animal studies with an emphasis on agents affecting mitochondrial function and its 
role in bipolar disorder were included. The search was augmented by manually searching the references of key papers and 
related literature. The results were presented as a narrative review.
Results: Mitochondrial agents offer new horizons in mood disorder treatment. While some negative effects have been 
reported, most compounds are overall well tolerated and have generally benign side-effect profiles.
Conclusions: The study of neuroinflammation, neurodegeneration, and mitochondrial function has contributed the 
understanding of bipolar disorder’s pathophysiology. Agents targeting these pathways could be a potential therapeutic 
strategy. Future directions include identification of novel candidate mitochondrial modulators as well as rigorous and well-
powered clinical trials.
Keywords: adjunctive, bipolar disorder, complimentary therapies, mitochondriaSignificance Statement Box Sample
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Introduction
Bipolar disorder (BD) is a complex illness with an approximate 
prevalence of 1% (Ferrari et al., 2016). It can cause marked dis-
ability and social impairment, particularly among people who 
experience continued subthreshold symptoms between acute 
phases, with depression being the greatest contributor (Judd 
et al., 2008).
Current pharmacological treatment offers limited efficacy 
overall, either in preventing relapses or recovery from acute 
episodes of depression (Perlis et  al., 2006). The current treat-
ment for the maintenance phase is mood stabilizers (Chen 
et al., 1999; Machado-Vieira et al., 2009; Oikawa and Sng, 2016). 
Antipsychotics and antidepressants are prescribed both in acute 
phases and maintenance phases, especially when subthreshold 
symptoms remain. While antipsychotics and mood stabilizers 
tend to effectively treat mania (Perlis et al., 2006), the treatment 
of bipolar depression is more challenging, as these agents may 
not improve depressive symptoms (Calabrese et al., 2007; Sachs 
et  al., 2007), and treatment with antidepressants may induce 
phase switching, particularly with monotherapy (Post et  al., 
2006; Viktorin et  al., 2014). An additional limitation to effec-
tive treatment options is the current lack of understanding of 
the underlying pathophysiology of bipolar depression (Sigitova 
et  al., 2017). Therefore, several new biological hypotheses are 
emerging, including neuro-inflammation (Naaldijk et al., 2016), 
neurodegeneration (Myint and Kim, 2014), and, relevant to the 
current review, mitochondrial dysfunction (Kato and Kato, 2000; 
Kato, 2007, 2010).
Different lines of evidence implicate mitochondrial impair-
ment in BD. A higher prevalence of mood disorders is reported 
in people with mitochondrial diseases compared to the gen-
eral population (Fattal et al., 2007). Furthermore, morphological 
abnormalities and marginal distribution of mitochondria were 
reported both in postmortem prefrontal cortex samples and 
peripheral cells from living BD patients. These findings were 
controlled for lithium treatment (Cataldo et al., 2010). A plethora 
of molecular data also confirms abnormal energy metabolism 
in BD. Indeed, postmortem studies have reported higher lactate 
concentrations in the brain of people with BD, which suggests a 
shift from oxidative phosphorylation to glycolysis (Dager et al., 
2004). This observation has been supported by similar studies 
using magnetic resonance spectroscopy (Stork and Renshaw, 
2005) and cerebrospinal fluid studies (Regenold et  al., 2009). 
Val66met, a brain-derived neurotrophic factor polymorphism 
that has been associated with BD, results in lower prefrontal 
cortex phosphocreatine (PCr) and creatine levels in BD patients 
(Frey et al., 2007).
Electron transport chain complex I is decreased in both lev-
els and activity in BD patients (Andreazza et al., 2010). Moreover, 
BD patients downregulate nuclear transcripts for proteins of 
the entire electron transport chain when subject to glucose 
deprivation, while controls seem to have the opposite response 
(Naydenov et al., 2007). There is also robust evidence of increased 
lipid peroxidation and alterations in calcium metabolism in BD 
(Munakata et  al., 2004; Kato, 2008). A  decrease in the expres-
sion of genes regulating oxidative phosphorylation and pro-
teasome degradation in BD patients in comparison to patients 
with schizophrenia (SZ) and healthy controls was also shown 
(Konradi et al., 2004). High energy requirements in the brain may 
also increase the production of reactive oxygen species (ROS), 
potentially damaging mitochondria themselves, resulting in an 
exacerbation of mitochondrial energy production failure (Hagen 
et al., 2002a).
Some already approved drugs for BD treatment affect mito-
chondrial function. Lithium and valproic acid may induce 
selective complex III and V phosphorylation and increase 
energy production (Corena-McLeod et al., 2013). Lithium treat-
ment increased electron transport chain complex I expression 
and activity in postmortem brain studies (Sun et  al., 2006a). 
Lithium has also been robustly associated with lower oxidative 
stress levels (Khairova et al., 2011; Banerjee et al., 2012; de Sousa 
et al., 2014) and a reversal of mitochondrial calcium alterations 
(Machado-Vieira et  al., 2011). Atypical antipsychotics increase 
superoxide dismutase gene expression and have antiapoptotic 
properties (He et al., 2009).
As our understanding of the pathophysiology of BD increases, 
new compounds targeting mitochondrial function are of inter-
est. The aim of this review is to give an update on potential 
interventions for BD that act via modulation of mitochondrial 
function (see Table 1). Where available, data from randomized 
controlled trials were preferred. However, where no clinical data 
exist, data from case reports or open-label studies were also 
discussed.
Mitochodrial Agents
N-Acetyl Cysteine
N-acetyl cysteine (NAC) is increasingly being used as an adjunc-
tive therapy in psychiatry (Berk et al., 2013). Its use across psy-
chiatric disorders is due to the number of mechanisms of action 
relevant to mental illness. In addition to providing rate-limiting
cysteine for glutathione production, NAC has also been shown to 
be an antiinflammatory, enhance neurogenesis, decrease apop-
tosis, modulate glutamate pathways, and, importantly, alter
mitochondrial activity (Samuni et al., 2013). In both mouse (R6/1) 
and rat (3-nitropropionic acid) models of Huntington’s Disease,
NAC has been shown to restore mitochondrial respiration
(Wright et al., 2015) and complex activity (Sandhir et al., 2012). 
Restoration of mitochondrial respiration has also been shown in 
rat models of traumatic brain injury as well as improvements in 
mitochondrial complex activity and mitochondrial glutathione
(Patel et al., 2014).
There is promising clinical evidence in support of adjunc-
tive NAC in diverse psychiatric disorders (Deepmala et al., 2015). 
A systematic review and meta-analysis has shown that overall, 
adjunctive NAC treatment seems beneficial for both unipolar 
and bipolar depression (Fernandes et al., 2016).
To date, there have been 2 multi-site trials of NAC specifi-
cally exploring its use as an adjunctive treatment for BD. Several 
substudies have also been reported from these data. The initial 
study was conducted in participants with BD (n = 75) that were 
experiencing any symptoms (or euthymic). At 6  months post-
baseline, participants that received 2000  mg/d NAC (in addi-
tion to standard treatment) reported improved measures of BD 
symptoms, functioning, and quality of life. This improvement 
persisted up to 4 weeks following NAC treatment cessation. 
Adverse effects did not significantly differ between the NAC and 
placebo groups (Berk et al., 2008).
Posthoc exploratory analyses were performed on a variety of 
data from this trial to assist in identifying who might benefit 
most from adjunctive NAC treatment in BD. This series of stud-
ies included the investigation of mania (or hypomania), bipolar 
II, major depressive episodes, cognition and comorbid systemic 
illness (Magalhães et al. 2011a, 2011b, 2013; Dean et al., 2012). 
When exploring major depressive episodes within the context 
of a BD sample, there were improvements following adjunctive 
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NAC compared with placebo (Magalhães et  al., 2011b). The 
investigation of those experiencing mania indicated within-
group improvements in the NAC group (Magalhães et al., 2013). 
Similarly, when exploring a subgroup of participants (n = 14) 
with bipolar II (divided in 2 groups of 7 patients each rand-
omized to placebo or NAC), NAC was found to improve symp-
toms in 6/7 participants, compared with 2/7 in the placebo 
group (Magalhães et al., 2011a). NAC was also shown to improve 
functional outcomes for people experiencing cardiovascular or 
endocrine comorbidities when compared to those who did not 
(Magalhães et al., 2012). Finally, a paper on posthoc analyses has 
reported no change in cognition in a small subset of participants 
following NAC (Dean et al., 2012).
The next study included a maintenance design with an ini-
tial open-label phase. Participants were given 2000 mg/d of NAC 
(n = 149) for a total of 8 weeks and were then randomized to con-
tinuation of adjunctive NAC treatment or a placebo. The open-
label phase showed significant improvements in participants 
experiencing bipolar depression (Berk et al., 2011). However, in 
the maintenance (randomized) phase, participants in both arms 
generally stayed well, which resulted in no significant treatment 
effects (Berk et al., 2012).
We further searched ANZCTR and Clinicaltrials.gov to ascer-
tain if there are upcoming studies in this area. A protocol has 
been published describing a study of NAC and a combination 
of other agents that enhance mitochondrial function, compared 
with placebo, over 16 weeks of treatment (Dean et al., 2015).
Overall, NAC is a potentially useful adjunctive therapy 
for BD and, in particular, bipolar depression during the acute 
phase. NAC has been shown to enhance mitochondrial func-
tion in preclinical models. However, no clinical studies that have 
investigated NAC for BD have evaluated outcomes related to 
mitochondrial function. Further research is required to explore 
the interactions of NAC clinical efficacy and changes in rele-
vant pathways, including pathways relevant to mitochondrial 
function.
Coenzyme Q10
Coenzyme Q10 (CoQ10), also known as ubiquinone, is a power-
ful lipid-soluble antioxidant that reduces the flow of electrons 
on the ROS-producing regions of Complex I, II, and III of the 
mitochondria (Lenaz et al., 2002; Nierenberg et al., 2013). CoQ10 
reduces ROS by neutralizing the free radical alpha-tocopheroxyl 
to alpha-tocopherol (vitamin E) and plays a role in the bio-
synthesis of adenosine triphosphate (ATP) (Morris et al., 2013; 
Nierenberg et al., 2013). The genes associated with these com-
plexes and the transportation of electrons across them are 
expressed differently in BD compared with healthy controls 
(Sun et al., 2006b). Supplementary CoQ10 has poor oral bioavail-
ability; however, it does cross the blood-brain barrier (Matthews 
et al., 1998).
Morris et al. (2013) discussed the reduction in CoQ10 levels 
in psychiatric and mitochondrial disorders such as depres-
sion, chronic fatigue syndrome, fibromyalgia, and Parkinson’s 
disease and postulated that CoQ10 supplementation could be 
a treatment for these disorders. However, a meta-analysis of 
CoQ10 supplementation compared with placebo showed no 
significant benefits for participants with Parkinson’s disease 
(Negida et al., 2016).
There have been several studies proposing the use of CoQ10 
supplementation as a mitochondrial enhancing agent in gen-
eral and for BD in particular (Morris et  al., 2013; Nierenberg 
et al., 2013). Despite this, there have been only 2 studies directly 
looking at CoQ10 supplementation and BD. One study explored 
CoQ10 in combination with other mitochondrial agents (such as 
NAC and b-group vitamins) as an adjunctive treatment for bipo-
lar depression (Dean et al., 2015). This study has been completed 
but results are still pending.
Forester et al. (2012) investigated an 8-week intervention of 
CoQ10 in a sample of 10 outpatients aged 55  years and older 
with a DSM-IV diagnosis of bipolar depression in an 8-week 
study. Participants were administered CoQ10 and compared 
with 8 healthy controls who did not receive CoQ10 supplemen-
tation. The maximum dose of CoQ10 was 1200 mg/d, starting at 
400 mg/d and titrated up by 400 mg/d every 2 weeks. Participants 
on CoQ10 showed modest but significant improvements in 
their depression symptoms (measured on the Montgomery–
Åsberg Depression Rating Scale MADRS) over the 8-week study. 
Furthermore, this study also investigated mitochondrial func-
tion via phosphorus magnetic resonance spectroscopy and 
reported no significant differences between groups for creatine 
kinase (a mitochondrial protein). This small study is limited by 
the sample size and lack of placebo control but highlights the 
potential of CoQ10 as an antidepressant and treatment for BD.
Alpha-Lipoic Acid
Alpha-lipoic acid (ALA), also known as thioctic acid, is a pleio-
tropic substance (Gomes and Negrato, 2014). ALA is a strong 
antioxidant (Suzuki et al., 1991; Moini et al., 2002). It increases 
levels of glutathione (Han et  al., 1997; Yamada et  al., 2011; 
Kleinkauf-Rocha et  al., 2013), raises hepatocyte ascorbate lev-
els (Lykkesfeldt et al., 1998; Michels et al., 2003), downregulates 
nuclear factor kappa-light-chain-enhancer of activated B cells 
(DeMarco et al., 2004), and is a metal chelator (Ou et al., 1995; 
Suh et al., 2005), an antiviral in glial cells (Scumpia et al., 2014), 
and a glucose uptake promoter (Estrada et al., 1996; Henriksen 
et al., 1997; Saengsirisuwan et al., 2004), increasing GLUT4 levels 
and insulin action (Hughes et al., 1993). Relevant to the current 
review, ALA also has a role as a mitochondrial agent. It can be 
endogenously synthesized in the mitochondria where it acts as 
a coenzyme for the formation of pyruvate dehydrogenase and 
α-ketoglutarate—both essential components of the Krebs cycle. 
Because pyruvate dehydrogenase converts pyruvate to acetyl 
CoA, ALA decreases lactate levels, thus inhibiting glycolysis 
(Gomes and Negrato, 2014). It also modulates the key regulator 
of mitochondrial biogenesis, peroxisome proliferator-activated 
receptor-gamma coactivator-1alpha (PPAR-GC-1α) (Liu, 2008). 
PPAR-GC-1α stimulation has been linked to neuroprotection and 
its suppression to mitochondrial dysfunction and neurodegen-
eration (Cui et al., 2006; St-Pierre et al., 2006). ALA also affects 
the mitochondrial pathway of apoptosis, prompting research in 
oncology as an agent with antimetastatic potential (Dörsam and 
Fahrer, 2016). This provides a rationale for its action in mood and 
cognitive disorders.
In a corticosterone-induced model of depression in mice, ALA 
showed antidepressant properties and reversed brain-derived 
neurotrophic factor reduction in the hippocampus and striatum 
(de Sousa et al., 2015). In a d-amphetamine-induced model of 
mania, ALA was able to both prevent and reverse symptoms 
with comparable efficiency to lithium (Macêdo et al., 2012).
Only one clinical trial has explored ALA as an adjunctive 
treatment for bipolar depression. The trial tested a combina-
tion of ALA (600–1800 mg/d) and acetyl-L-carnitine (ALC) (1000–
3000 mg/d) or placebo for 12 weeks in 40 participants with bipolar 
depression. Previous treatment (stable for at least 4 weeks) was 
continued. The primary outcome was depression, measured on 
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the MADRS. No significant changes were found between groups 
(Brennan et al., 2013). As the authors note, the shorter duration 
of the study (12 weeks) compared with a positive RCT of a mito-
chondrial agent (NAC) in BD (24 weeks) (Berk et al., 2008), the 
inclusion of bipolar I and II types, concomitant medication use, 
and possible low oral bioavailability of the agents are all poten-
tial confounders that should be addressed.
More research is required to determine the efficacy of 
ALA in BD. Moreover, there is one study (described earlier) in 
bipolar depression that is currently being completed that 
includes a combination of agents including ALA, ALC, and NAC 
(ACTRN12612000830897).
ALC
In addition to the role of ALC in mitochondrial β-oxidation and 
energy production (Hoppel, 2003), ALC has antioxidant properties 
(Gülçin, 2006; Mescka et al., 2011). Additionally, ALC has been pro-
posed to mediate the transfer of acetyl groups for acetylcholine 
synthesis, modulate nerve growth factors and gene expression 
(Nałecz and Nałecz, 1996; Binienda, 2003; Nacz et al., 2004), and 
counter glutamate-induced excitotoxicity (Zanelli et al., 2005).
Data from animal models provide further evidence for ALC’s 
therapeutic potential due to its role as an antioxidant and in 
improving mitochondrial energy production (Rao et  al., 1997; 
Aureli et al., 1998; Hagen et al., 2002b; Al-Majed et al., 2006), its 
neuroprotective action in trauma (Karalija et al., 2014) and ische-
mia (Rosenthal et al., 1992; Barhwal et al., 2007), its antidepres-
sant effect in the forced swim test (FST) (Wang et al., 2015), and 
its ability to reverse memory loss in older rats (Liu et al., 2002).
Two patients with geriatric depression treated with ALC 
showed increases in PCr and β-nucleoside triphosphate (β-NTP) 
levels (Pettegrew et al., 2002). PCr serves as a reservoir for high-
energy phosphates, and β-NTP is acknowledged as an index of 
brain levels of ATP. Thus, these results provide support for a link 
between the antidepressant action of ALC and improved energy 
production within the brain.
However, the only RCT in BD reported no effect when admin-
istered in combination with ALA (Brennan et  al., 2013) (see 
above). Furthermore, the change in PCr and β-NTP, previously 
found in geriatric depression patients (Pettegrew et  al., 2002), 
was not observed (Brennan et al., 2013). Two case reports of ALC-
associated relapse in BD also suggest some caution with clin-
ical use. The first case-reports detail a psychotic episode in a 
known BD type I patient, 5 days after starting treatment with 
nutritional supplements including vitamin C, vitamin E, and 
ALC (500 mg/d) (Evcimen et al., 2007). Manic symptoms associ-
ated with self-prescribed ALC treatment (2000 mg/d) in a man 
with BD type I resolved 3 days after cessation of ALC (Goodison 
et al., 2016).
S-Adenosylmethionine
S-Adenosylmethionine (SAMe) results from the combination
of ATP and methionine and plays a crucial role as a methyl
donor in reactions involving methyltrasnferases (Bottiglieri, 
2002). SAMe is also a precursor molecule for glutathione pro-
duction, which plays an essential role in reducing oxidative
stress. In the brain, SAMe repairs and degrades proteins and
activates thyroxine hydroxylase through methylation, which
is critical in the synthesis and regulation of monoamines (i.e.,
dopamine, serotonin), which are known to be dysregulated in BD 
(Bottiglieri et al., 2000, 2002). Recently, an RCT of SAMe as an add-
on to an approved mood stabilizer in 20 participants with BD
(type I and II) was conducted. To enroll, subjects were required 
to have not responded previously to either 2 antidepressants (of 
different classes) or to 2 different mood stabilizers. No signifi-
cant differences were observed in MADRS, Hamilton Rating Scale 
for Depression (HAM-D), or Young Mania Rating Scale (YMRS) 
between the SAMe and placebo groups. No switches to mania 
were reported (Murphy et al., 2014). Carney et al. (1989) reported 
3 open label trials and 1 placebo-controlled trial after a drug-
free period of at least 7 days. There were 14 unipolar depression 
and 11 BD participants. Nine of the 11 BD participants switched 
to hypomania, mania, or “elevated mood.” The other 2 partici-
pants did not respond to treatment (Carney et al., 1989). In an 
open-label trial of i.v. SAMe monotherapy for depression, 7 of 
9 patients improved or had depression remission. There were 2 
case reports of mood switch in BD patients, 1 of mania, and 1 of 
hypomania (Lipinski et al., 1984). Due to the potential for manic 
switching, SAMe for BD should be investigated with caution. In 
unipolar depression, a meta-analysis in 2002 showed that SAMe 
is superior to placebo improving HAM-D scores (Hardy et  al., 
2003). A recent systematic review collected clinical information 
from 115 clinical trials and 17 preclinical studies on the effect of 
SAMe on several neuropsychiatric conditions. Positive but lim-
ited evidence was found for the use of SAMe in major depressive 
disorder (MDD) as both a monotherapy and adjunctive therapy 
(Sharma et  al., 2017). Recently, 2 studies have demonstrated 
benefits of SAMe as an augmentation antidepressant therapy. 
In a 6-week, double blind, placebo RCT with serotonin reuptake 
inhibitors or serotonin norepinephrine reuptake inhibitors non-
responders, participants undergoing SAMe augmentation had 
lower HAM-D score and higher remission rates (final HAM-D 
score <8) than placebo (Papakostas et al., 2010).
Creatine Monohydrate
Creatine is the precursor of PCr. Long-term decrease of PCr 
decreases ATP production, attributable to mitochondrial dys-
function (Erecińska and Silver, 1989). Oral supplementation 
of creatine monohydrate increases creatine and brain con-
centrations of PCr (Dechent et al., 1999; Lyoo et al., 2003a). In 
BD, decreased PCr concentrations have been reported (Stork 
and Renshaw, 2005). Furthermore, creatine has been shown 
to have antioxidant properties in animal models of oxidative 
stress (Sullivan et al., 2000; Tarnopolsky and Beal, 2001; Lawler 
et al., 2002)
A 4-week open-label trial with 10 participants experienc-
ing treatment-resistant depression (8 unipolar and 2 bipolar) 
showed improved depression scores with 3 to 5  g/d creatine 
monohydrate augmentation, provoking switch to elevated mood 
in both BD patients (Roitman et  al., 2007). Two trials focusing 
on a combination of cytidine and creatine in bipolar depression 
are currently being conducted (NCT01543139; NCT02625779). 
A  6-week, double blind, placebo RCT to evaluate the efficacy 
of creatine monohydrate as an adjunctive therapy for BD type 
I depression (NCT01655030) is also currently recruiting.
Melatonin
Melatonin regulates several homeostatic processes such as cir-
cadian rhythm maintenance, growth hormone stimulation, and 
insulin secretion (Paredes et al., 2014; Simões et al., 2016; Zhang 
et  al., 2016). Relevant to mitochondrial physiology, melatonin 
improves oxidative phosphorylation, increasing the activity of 
the I and IV dose-dependent complexes and membrane fluid-
ity and closes the mitochondrial permeability transition pore 
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(a protein complex spanning the inner and outer mitochon-
drial membranes), preventing ATP depletion and necrotic cell 
death (Acuña-Castroviejo et al., 2001, 2007; Martín et al., 2002; 
Leon et al., 2005). Moreover, melatonin and some of its metabo-
lites play an important antiinflammatory and antioxidant role 
through scavenging oxygen and nitrogen-based ROS (López-
Burillo et  al., 2003; Korkmaz et  al., 2009). Melatonin directly 
boosts mRNA expression of genes implicated in the production 
of glutathione peroxidase and superoxide dismutase, 2 antioxi-
dant enzymes (Rodriguez et al., 2004; Acuña-Castroviejo et al., 
2007; Anderson and Maes, 2014). Furthermore, peripheral mela-
tonin, produced outside the brain, is decreased in BD compared 
with healthy controls, suggesting supplemental melatonin may 
be a relevant intervention in this population (Anderson and 
Maes, 2014).
In an 8-week, double blind, placebo control trial, 44 par-
ticipants (24 participants with SZ and 20 with BD) treated with 
second-generation antipsychotics received low dosages of mela-
tonin (5 mg/d) and placebo. The melatonin group showed lower 
diastolic blood pressure and less weight gain, these results being 
greater in the BD group (Romo-Nava et  al., 2014). In an open-
label trial, melatonin improved mania scale scores and sleep-
ing patterns (Bersani and Garavini, 2000) but had no significant 
effects on mood or sleep in a double-blind, placebo-controlled 
trial using the same dose with 5 rapid-cycling DSM-III-R BD 
patients (Leibenluft et al., 1997).
McElroy et  al. (2011) tested ramelteon (a highly selective 
melatonin MT1/MT2 receptor agonist) as an adjunctive treat-
ment in 21 outpatients with bipolar I  disorder with mild-to-
moderate manic symptoms and sleep disturbance in an 8-week, 
double-blind, fixed-dose (8 mg/d) study. A global improvement 
in a global rating of depressive symptoms was reported; how-
ever, no significant differences in ratings of insomnia, mania, 
and global severity of illness were observed. Norris et al. (2013) 
conducted a double-blind, randomized, placebo-controlled trial 
of adjunctive ramelteon in euthymic bipolar patients with sleep 
disturbances and reported that participants receiving ramelteon 
were significantly less likely to relapse compared with placebo. 
Recently, a RCT comparing placebo with sublingual ramelteon in 
different dosages (0.1 mg, 0.4 mg, 0.8 mg, once daily) as adjunct-
ive maintenance therapy in stable BD patients did not show sig-
nificant differences between any dose of ramelteon and placebo 
(Mahableshwarkar et al., 2017). The study was terminated before 
the expected sample size due to meeting the futility criteria. All 
studies showed ramelteon was well tolerated and associated 
with no serious adverse events.
Agomelatine (an agonist of melatonin 1 and 2 receptors and 
antagonist of serotonin 2C receptors drug) has also been inves-
tigated as an adjunctive treatment for bipolar depression. In an 
open-label trial with 21 type I BD patients in a severe depres-
sive episode (14 treated with lithium and 7 with valpromide), 
agomelatine was added at 25 mg/d for at least 6 weeks and, if 
participants opted-in, up to 1 year. At week 6, 81% of patients 
improved >50% in HAM-D score from baseline and almost 50% 
in the first study week. Three patients switched to mania or 
hypomania from the sixth week until the complete year fol-
low-up (Calabrese et al., 2007). In a similar study, 28 type II BD 
patients in a severe depressive episode (11 treated with lithium 
and 17 with valproate) were treated with agomelatine at fixed 
dosages of 25 mg/d from at least 6 weeks to a possible 30-week 
extension. At 6 weeks, 64% of patients improved >50% in HAM-D 
score from baseline and 86% responded at 36 weeks. There were 
4 drop-outs in total due to polarity change (1 manic and 3 hypo-
manic episodes) (Fornaro et  al., 2013). Recently, 344 type I  BD 
patients undergoing a current major depressive episode that 
were treated with lithium or valproic acid for at least 6 weeks 
were randomized to treatment with agomelatine or placebo 
(n = 172 each group) in a double-blind study (Yatham et al., 2016). 
No significant differences between both groups in MADRS total 
score or response or remission rates from baseline to endpoint 
were found. The number of manic or hypomanic symptoms was 
comparable between both groups at each assessment time. As a 
number of sites had placebo response rates of 100%, when these 
were excluded in a posthoc analysis, a signal favoring agomela-
tine over placebo emerged. While the meta-analyses in unipolar 
depression confirm the antidepressant effects of agomelatine 
(Singh et al., 2012; Taylor et al., 2014), melatonin supplementa-
tion did not significantly improve treatment or prophylaxis of 
unipolar depression (Hansen et al., 2014).
Pyrimidines
The pyrimidine nucleosides such as uridine, triacetyluridine, and 
cytidine have effects on mitochondrial function, glutamatergic 
transmission, catecholamine synthesis, and cerebral phospho-
lipid metabolism, which has been linked to the pathophysiology 
of BD (Yoon et al., 2009; Kondo et al., 2011). Uridine (1000 mg/d) 
was studied in a 6 weeks open-label trial of 7 teenagers with 
bipolar depression. Children’s Depression Rating Scale-Revised 
and the Clinical Global Impressions scale were used to measure 
the treatment results. Uridine was well tolerated and depressive 
symptoms decreased (Kondo et al., 2011).
In another 6-week study (n = 20), 18 g/d day of triacetyluridine 
(TAU), a uridine prodrug, or placebo was given to patients with 
bipolar depression. BD patients who had a reduction in MADRS 
scores ≥50% showed a greater difference in pH changes (assessed 
by phosphorus magnetic resonance spectroscopic imaging 
(PMRSI)) compared with TAU nonresponders, suggesting that 
TAU treatment can have benefits in depressive symptoms and in 
mitochondrial function (Jensen et al., 2008). Cytidine, available 
from dietary sources and converted in uridine in the human 
body, was investigated in a 12-week, randomized, placebo trial 
with 35 patients with bipolar depression. Participants were ran-
domly given valproate plus placebo or valproate plus cytidine. 
At 2, 4, and 12 weeks, the cerebral levels of glutamate/glutamine 
were measured using PMRSI. The results showed that cytidine 
supplementation resulted in earlier improvement in symptoms 
of depression and greater reduction in glutamate/glutamine lev-
els. These data suggest that the observed therapeutic effect of 
cytidine may be mediated via a decrease in cerebral glutamate/
glutamine levels (Yoon et al., 2009).
Choline
Choline is a constituent of the neurotransmitter acetylcholine, 
a major methyl-donor, and needed for structural integrity and 
intracellular signaling within cell membranes. In an open-label 
trial, Stoll et al. (1996) studied the effects of lithium augmenta-
tion with choline in 6 rapid-cycling BD outpatients. Five partici-
pants experienced a reduction in manic symptoms and 4 had 
a reduction in all mood symptoms during choline therapy. The 
impact on depression was variable. Lyoo et al. (2003b) studied 8 
lithium-treated, rapid-cycling BD I and II patients randomized 
to receive either choline or placebo, and reported significantly 
decreased brain purine levels, a marker of energy metabolism.
Vitamin A
Both deficient and excessive levels of vitamin A disrupt many 
human systems, including the central nervous system (CNS) 
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(Chapman, 2012). Vitamin A  is required for vision, gene tran-
scription, immune system, and skin cell differentiation 
(Haybaeck et al., 2015). The role of vitamin A  in gene expres-
sion and its role in redox activation suggest a possible role as 
a mitochondrial agent in the treatment of BD. Vitamin A also 
plays a very important role as a co-factor in redox activation, 
binding to protein kinase C (Hoyos et  al., 2012; Hammerling, 
2016). Retinoid receptors are concentrated in the striatum, 
hippocampus, frontal cortex, and hypothalamus, all key brain 
areas involved in depression (Bremner et  al., 2012). Being 
involved in neuroplasticity in the hippocampus, vitamin 
A  deficiency can also affect memory, appetite, and growth 
(Haybaeck et al., 2015; Stoney and McCaffery, 2016). Haybaeck 
et al. (2015) found the brains of patients with SZ, BD, or MDD to 
have significantly increased expression of vitamin A-inducible 
or induced gene 1, pointing to altered signaling pathways. 
Another study found mRNA levels of key elements of vita-
min A signaling were significantly reduced in the postmortem 
dorsolateral prefrontal cortex/anterior cingulate cortex from 
elderly depressed patients (Qi et al., 2015). A similar signal was 
detected in a chronic unpredictable mild stress model in rats 
(Qi et  al., 2015). There is evidence of a link between isotreti-
noin use and depression and suicide (Bremner et al., 2012; Hu 
et al., 2016), clinical exacerbation of BD, and possibly to psych-
osis (Ludot et al., 2015). Vitamin A therapy at high doses is also 
associated with cognitive decline (de Oliveira et al., 2009; 2015) 
and increased levels of oxidative stress markers in both human 
and animals (de Oliveira et al., 2009).
Vitamin C
Vitamin C is an antioxidant capable of scavenging free radi-
cals and other ROS formed in cell metabolism. In addition to 
its role as an antioxidant, vitamin C is a co-substrate of many 
important oxidoreductases and may regulate gene transcrip-
tion (Arrigoni and de Tullio, 2002). Because of these characteris-
tics, vitamin C has been tested as a possible adjunctive therapy 
in psychiatric disorders. A  double-blind, placebo RCT in high 
school students showed lower levels of anxiety after 14 days of 
vitamin C supplementation compared with placebo (de Oliveira 
et al., 2015). Positive results were also reported in a 6-month, 
double-blind, randomized control pilot trial with 1000  mg/d 
vitamin C as an adjunct to 10  to 20 mg/d fluoxetine in children 
(n = 24) diagnosed with MDD (Amr et  al., 2013). However, the 
only RCT testing vitamin C as an adjuvant (1000 mg/d) in the 
treatment of adults (n = 43) with MDD (added to 60  mg/d cit-
alopram) showed no statistically significant results (Sahraian 
et al., 2015).
In BD, vitamin C was proposed as a treatment in a dou-
ble-blind, placebo control cross-over trial, where 23 BD par-
ticipants receiving 3  g/d of vitamin C reported improvement 
in depressive symptoms (Naylor and Smith, 1981). Kay et  al. 
(1984) conducted a 28-day, double-blind, randomized active-
control study with 61 BD inpatients (29 with manic symptoms 
and 32 with depressive symptoms). The depressed participants 
received either 150 mg/d amitriptyline (n = 14) or 4 g/d vitamin 
C plus 4 g/d ethylene diamine tetra acetic acid (EDTA) (n = 18). 
The manic participants were also divided into 2 groups—13 
were medicated with 800 g/d lithium and 16 received only vita-
min C plus EDTA. Manic participants responded better to lith-
ium than to vitamin C. There was no significant difference in 
depression symptoms between amitriptyline or vitamin C in 
the depressed group on HAM-D and Beck Depression Inventory 
(BDI) ratings.
Vitamin D
Vitamin D is a fat-soluble antioxidant involved in the regula-
tion of calcium and phosphate metabolism. Moreover, vitamin 
D is implicated in the production of melatonin and in seasonal 
affective disorder (Gloth et al., 1999). The association between 
low levels of vitamin D and mood disorders (MDD, BD, and dys-
thymia) has been established (Anglin et al., 2013; Belzeaux et al., 
2015), and it was also identified as a risk factor for develop-
ment of postpartum depression in pregnant women (Robinson 
et  al., 2014). Furthermore, vitamin D influences monoamine 
metabolism by modulating the hypothalamic-pituitary-adrenal 
axis through vitamin D receptors (VDRs) (Puchacz et al., 1996; 
Prüfer et  al., 1999; Eyles et  al., 2005). VDRs also affect nuclear 
transcription, regulate the expression of the dopamine receptor 
gene (Trinko et al., 2016), and may also be involved in the regu-
lation of mitochondrial function and lipid metabolism (Silvagno 
and Pescarmona, 2017). VDR is now known to translocate into 
mitochondria, which raises the possibility of vitamin D having 
a direct impact on cellular bioenergetics by altering mitochon-
drial function and VDR to work as a modulator of energy balance 
in humans (Silvagno and Pescarmona, 2017). Studies on cancer 
cells (Consiglio et al., 2014), keratinocytes (Consiglio et al., 2015), 
adipocytes (Ricciardi et  al., 2015), and VDR-null mutant mice 
(Wong et al., 2011) found that VDR can influence the transcrip-
tion of proteins of the mitochondria respiratory chain, inhibiting 
it and redirecting Krebs cycle intermediates toward biosyn-
thesis (Consiglio et  al., 2014). However, establishing the treat-
ment effect of vitamin D supplementation has been somewhat 
problematic as studies are likely too heterogeneous (including 
depression, seasonal affective disorder, obesity, postmenstrual 
tension, and hospitalized patients). Therefore, varying the selec-
tion criteria wields both positive and negative meta-analysis 
results: A meta-analysis of 15 RCTs (with samples between 15 
and 2117)  was favorable for vitamin D supplementation (≥800 
I.U. daily) (Spedding, 2014), while another meta-analysis using
6 RCTs (n = 1203, 71 depressed) showed no significant effect of
vitamin D supplementation on postintervention depression
scores (Li et  al., 2014). A  more recent double-blind RCT of 40
MDD patients on vitamin D monotherapy (50 kIU/d for 8 weeks)
showed beneficial effects on the depressive symptoms meas-
ured by the BDI on indicators of glucose homeostasis and on
oxidative stress levels (Sepehrmanesh et  al., 2016). Regarding
BD, an 8-week open-label trial tested the effect of adjunctive
vitamin D supplementation in mania in young bipolar spectrum 
disorder patients (aged 6–17 years old). There was a significant
decrease in YMRS scores and improvement in levels of glutam-
ate and γ-aminobutyric acid (GABA) measured in the anterior
cingulate cortex (Sikoglu et al., 2015).
Vitamin E
Vitamin E or tocopherol is a fat-soluble antioxidant, which has a 
stabilizing function in the mitochondrial membrane attributed 
to radical scavenging and lipid peroxidation reduction (Kagan 
et  al., 1990; Pham-Huy et  al., 2008). Studies have suggested 
that vitamin E may be more effective when combined with 
CoQ10 or vitamin C (Kontush and Schrkatolina, 2004; Dhitavat 
et al., 2005). To our knowledge, the efficacy of vitamin E in BD 
or MDD has not been examined. Some animal studies found 
positive results—chronic administration of high doses of vita-
min E improved lifespan, neurological performance, and brain 
mitochondrial function in aging mice (Navarro et  al., 2005). 
Likewise, studies in Alzheimer’s disease are also promising. 
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A multi-center RCT studied the effect of vitamin E supplemen-
tation in 613 participants with mild-to-moderate Alzheimer’s 
disease, medicated with memantine, and reported slower func-
tional decline and decreased caregiver burden (Dysken et  al., 
2014). A  cross-sectional and prospective study of 104 patients 
with Alzheimer’s disease showed reduced prevalence and inci-
dence of Alzheimer’s on those consuming vitamin E plus C sup-
plementation (Zandi et al., 2004). A clinical trial with combined 
therapy with vitamin C for MDD in elderly patients is now in the 
recruiting phase (NCT02793648).
Vitamin B Complex
The vitamin B complex contains water-soluble vitamins B1, 
B2, B3, B5, B6, B7, B9, and B12. They play an important role in a 
variety of critical brain pathways and participate in mitochon-
drial energy production and cellular function (Dean et al., 2012). 
Vitamin B complex is known to influence cognitive performance 
and mood. Its influence in CNS function has been suggested 
to occur in 2 interrelated ways: direct via of hypomethylation 
and indirectly by homocysteine levels resulting in structural 
changes in the brain (Calvaresi and Bryan, 2001). They often 
work in synergy and thereby are best administered as a complex 
(Dean et al., 2012).
Vitamin B9
Vitamin B9, or folate, is involved in the synthesis, repair, and 
methylation of DNA and in the formation of monoamine neu-
rotransmitters, thus being important in the pathogenesis of 
affective disorders (Mattson and Shea, 2003; Folstein et al., 2007; 
Miller, 2008; Sharpley et  al., 2014). Together with vitamin B12, 
vitamin B9 plays an essential role in mitochondrial energy pro-
duction through 1-carbon transfer pathways (Dean et al., 2015). 
Folate deficiency has been associated with several neuropsychi-
atric disorders, especially in inpatients (Hall et al., 1997; Dean 
et al., 2015) such as depression, BD, and cognitive dysfunction 
(Bell et al., 1990; Godfrey et al., 1990; Hasanah et al., 1997; Selhub 
et  al., 2000; Bryan et  al., 2002; Reynolds, 2002; Gilbody et  al., 
2007). Furthermore, in long-term lithium-treated patients, low 
serum folate levels were associated with higher affective mor-
bidity (Coppen and Abou-Saleh, 1982). Schou et  al. (1986) also 
found low levels of folate in untreated BD patients (25% lower 
than controls) and their normalization after 6 months of lith-
ium. Behzadi et al. (2009) conducted a preliminary RCT with 88 
BD type I  manic patients treated with sodium valproate and 
adjuvant folic acid (synthetic form of folate). After 3 weeks, 
a statistically significant difference in the YMRS was found. 
Another double-blind RCT of 75 lithium-treated BD patients 
on a daily supplementation of 200 μg folic acid for 52 weeks 
showed a significant reduction in affective morbidity (Coppen 
et al., 1986). L-methylfolate was also recently studied in the first 
open-label trial for bipolar depression. Ten patients with BD 
type I  on standard treatment for bipolar depression (but with 
no antidepressant) received 15 mg of folate daily for 6 weeks. 
A  55% improvement in depression symptom ratings (MADRS) 
and a small mean decrease in YMRS was found, suggesting 
its potential as BD adjunctive treatment (Nierenberg et  al., 
2017). L-methylfolate has potential as an adjunctive treatment 
for unipolar depression. Two multicenter sequential parallel 
comparison design trials were conducted with MDD patients 
(n = 148 and n = 75) with partial or no response to serotonin 
reuptake inhibitors. L-methylfolate supplementation was given 
for 30  days at the dosing of 7.5  mg/d and augmented later to 
15 mg/d in the following month in trial one. In trial two, 15 mg/d 
of L-methyfolate was given for 60  days. The second trial had 
positive results on primary outcomes—degree of improvement 
in depressive symptom score and response rate (Papakostas 
et al., 2012). Folic acid was also found to improve the therapeutic 
effect of fluoxetine in depressed patients in another 2 placebo-
controlled RCTs. Studies with samples of 127 and 42 patients 
with MDD, respectively, were treated with folic acid plus 20 mg 
of fluoxetine and showed greater improvement in the HAM-D 
and in the BDI (Coppen and Bailey, 2000; Venkatasubramanian 
et al., 2013). Moreover, long-term treatment of post-stroke sur-
vivors (n = 273) with folic acid, B6, and B12 was associated with 
a reduction in the risk for MDD (Almeida et al., 2010). The effect 
of vitamin B9 as a possible early intervention was studied in a 
double-blind, placebo RCT in healthy teenagers (n = 112) with 
increased familial risk of depression and BD. Folic acid did not 
reduce the incidence of a mood disorder diagnosis but may have 
delayed the first mood episode and its clinical presentation 
tended to be milder (Sharpley et al., 2014).
Vitamin B1
Vitamin B1, or thiamine, functions as a cofactor essential for the 
oxidative decarboxylation of the Krebs cycle (Depeint et al., 2006). 
Vitamin B1 deficiency is associated with neurological problems, 
including cognitive deficits and encephalopathy (Depeint et al., 
2006; Gibson et al., 2016). Healthy elderly women with marginal 
vitamin B1 deficiency experienced with thiamin supplementa-
tion a significant increase of appetite, body weight, energy, and 
activity, and decreased fatigue, improvement of sleep patterns, 
and of general well-being (Smidt et al., 1991).
Vitamin B3
Vitamin B3, or niacin, is a precursor for NADH and nicotinamide 
adenine dinucleotide phosphate, which is involved in more than 
500 enzymatic reactions pertaining to mitochondrial respira-
tion (oxidative phosphorylation), glycolysis, and lipid oxidation 
(Depeint et al., 2006). The potential of NADH as an antidepres-
sant was first tested in the FST model in Wistar rats, yielding 
a similar effect to fluoxetine (Rex et al., 2004). Vitamin B3 sup-
plementation was also shown to prevent development and pro-
gression of mitochondrial myopathy in mice (Khan et al., 2014). 
More relevant to BD, evidence of mood elevation was reported 
in a 54-year-old man with no previous mental illness, who had 
a manic episode after commencing vitamin B3 for his dyslipi-
demia (Loebl and Raskin, 2013).
Vitamin B6
Vitamin B6 refers to 3 primary forms: pyridoxine, pyridoxal 
phosphate, and pyridoxamine. The last 2 serve as coenzymes 
for protein metabolism, conversion of tryptophan to niacin, and 
neurotransmitter function. Some of the protective effect of vita-
min B6 may occur via modification of mitochondrial function 
by preventing the oxygen radical generation and lipid peroxida-
tion (Kannan and Jain, 2004). Higher dietary intake of vitamin 
B6 and folate was associated with lower prevalence of depres-
sion symptoms (measured with the Center for Epidemiologic 
Studies Depression Scale) in a large cross-sectional study of 
6517 community adolescents (aged 12 to 15)  (Murakami et al., 
2010). Another study in 38 healthy older men on 20 mg of vita-
min B6 supplementation showed cognitive benefits such as 
improved memory but failed to improve mood (Deijen et  al., 
1992). A double-blind RCT in 211 healthy women showed simi-
lar results (Bryan et al., 2002). Another 4-week, double-blind RCT 
with 14 geriatric depressed inpatients tested the augmentation 
of tricyclic antidepressant treatment with vitamins B1, B2, and 
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B6 (10  mg/d). The active vitamin group demonstrated greater 
improvement in scores on ratings of depression and cognitive 
function (Bell et  al., 1992). A  24-week, open-label clinical trial 
with 10 participants with SZ patients that were already receiving 
antipsychotics were given 1200–2400 mg/d of pyridoxamine. The 
patients had high levels of plasma pentosidine, a carbonyl stress 
biomarker. The results were measured with the Positive and 
Negative Syndrome Scale score and the Brief Psychiatric Rating 
Scale. Treatment augmentation with pyridoxamine showed 
partial results in participants with enhanced carbonyl stress; 
however, only 3 patients had reduction of psychopathology. 
Four patients showed improvement on iatrogenic parkinson-
ism. However, 2 patients had Wernicke’s encephalopathy-like 
adverse drug reactions, reversed by thiamine supplementation 
(Itokawa et al., 2018).
Vitamin B2
Vitamin B2 is a precursor of flavin adenine dinucleotide and fla-
vin mononucleotide and is required for electron transport chain 
in complexes I  and II. They work synergistically with other B 
vitamins for mitochondrial respiration (Depeint et  al., 2006). 
Henriques et  al. (2016) showed that vitamin B2 supplementa-
tion could functionally compensate for mitochondrial ß-oxida-
tion enzymes. Four nonrandomized trials have been reported 
effectively treating mitochondrial diseases with complex I and/
or complex II (Bernsen et al., 1993; Bugiani et al., 2006; Gerards 
et al., 2011) and III and IV (Ghezzi et al., 2010) deficiency.
Vitamin B5
Vitamin B5 is the precursor of CoA, important in the Krebs cycle 
and fatty acid oxidation. In vitro and in vivo studies suggest 
that vitamin B5 can restore ATP synthesis levels as well as the 
activity of antioxidant enzymes and can prevent the collapse of 
mitochondrial membrane potential (Depeint et al., 2006). There 
are established associations between vitamin B5 deficiency and 
neurodegenerative diseases, dermatitis, hypoglycemia, con-
vulsions, and encephalopathy with liver failure (Depeint et al., 
2006).
Vitamin B7
Vitamin B7 is a coenzyme for 5 mitochondrial carboxylases and 
is essential for growth, development, and normal mitochon-
drial and cellular functions, including fatty acid oxidation and 
gluconeogenesis. Reductions in vitamin B7 result in the loss of 
mitochondrial complex IV, which leads to increased production 
of oxidative species by the mitochondria (Depeint et al., 2006). 
Several clinical disorders are associated with B7 deficiency, such 
as cutaneous conditions (skin rashes, alopecia, and conjunctivi-
tis), neurological conditions (depression, seizures, paresthesia), 
and diabetes (Depeint et al., 2006).
Vitamin B12
Vitamin B12, or cobalamin, is a cofactor for methionine synthe-
sis, required for DNA and myelin synthesis and maintenance 
of neuronal integrity as well as neurotransmitter regulation. 
Vitamin B12 deficiency is a common but often under-recognized 
condition causing neurologic, cognitive, psychiatric, and mood 
symptoms (Lindenbaum et al., 1988; Issac et al., 2015). Further, 
deficiencies of B12, folate, or B6 can lead to macrocytic or per-
nicious anemia with symptoms of fatigue, psychomotor, cogni-
tive, and mood deficits (Selhub et al., 2009). In an RCT in elderly 
participants with depressive symptoms, long-term daily sup-
plementation with folic acid and vitamin B12 improved cogni-
tive functioning, particularly immediate and delayed memory 
performance (Walker et al., 2012). More relevant to BD, there is 
a case-report of an acute onset of mania in a 94-year-old man 
with no previous mental illness and profound cobalamin defi-
ciency who responded to cobalamin therapy (Jacobs et al., 1990). 
In a double-blind RCT of vitamin B12 supplementation in win-
ter seasonal affective disorder, no significant differences were 
found (Oren et  al., 1994). No benefit for B12 replacement was 
found in cognitive symptoms in dementia (van Dyck et al., 2009) 
or depressive symptoms in an elderly man (Ford et al., 2008).
Other Potential BD Agents
Taurine
Taurine is a free amino acid that has important functions as a 
neuromodulator and antioxidant. It protects against glutamate-
induced neurotoxicity and has been hypothesized to prevent 
membrane depolarization and mitochondrial energy failure 
(Timbrell et al., 1995; Ye et al., 2013). Recently, taurine has been 
reported to reduce oxidative stress and maintain mitochon-
drial function in cortical neurons (Xu et  al., 2015). Moreover, 
taurine acts as an agonist for glycine and γ-aminobutyric acid 
receptors (Albrecht and Schousboe, 2005). In the FST model in 
rats, taurine supplementation has antidepressant-like effects 
(Toyoda and Iio, 2013). In a double-blind RCT in people with first-
episode psychosis, taurine improved symptoms of depression 
and reduced psychotic symptoms as well as improved measures 
of functioning but failed to impact cognition (O’Donnell et al., 
2016). While a double-blind RCT in BD adolescents with a manic 
episode was conducted (CT00391001), the study was terminated 
and no results have been published. Another double-blind RCT 
was carried out but despite its completion, no results have been 
revealed at this time (NCT00217165).
Bezafibrate
An agonist of the PPAR usually prescribed as an hypolipidemic 
drug, bezafibrate can restore fatty acid oxidation activity in cells 
from carnitine palmitoyltransferase-2 and very-long-chain acyl-
CoA dehydrogenase deficiencies in in vitro conditions (Bastin 
et  al., 2008). Data suggest that the PPAR signaling pathway is 
directly implicated in mitochondrial physiology. Exposure to 
bezafibrate increased the transcription of HADHA and HADHB 
genes (responsible the encoding of alpha and beta subunit of 
the mitochondrial trifunctional protein) (Aoyama et  al., 1998), 
immune-detectable alpha and beta subunit proteins, activities 
of long-chain 3-hydroxyacylCoA dehydrogenase and long-chain 
3-ketoacylCoA thiolase, and stimulated fatty acid oxidation
capacities in human fibroblasts (Djouadi et al., 2016). To the best
of our knowledge, no clinical data are available in the literature
regarding the role of benzafibrate in psychiatry. However, an
8-week, open-label pilot trial of bezafibrate 400 mg/d added to
lithium in 20 participants with bipolar depression is being con-
ducted to assess its safety, tolerability, and antidepressant effi-
cacy (NCT02481245).
Conclusion
The study of neuroinflammation, neurodegeneration, and mito-
chondrial function has contributed to the understanding of 
BD’s pathophysiology and led to the exploration of agents tar-
geting these pathways. While some negative effects have been 
reported, compounds tested to date have been well-tolerated in 
the existing clinical data. Future directions include combinations 
of compounds targeting multiple mitochondrial pathways with 
potentially synergistic effects. Additionally, combinations with 
antioxidant or antiinflammatory agents could be feasible next 
steps to achieve better outcomes due to the role of inflammation 
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and oxidative stress in generation and maintenance of mito-
chondrial dysfunction (Rodriguez et al., 2007; Tarnopolsky, 2008). 
Identification of novel candidate mitochondrial modulators as 
well as rigorous and well-powered clinical trials are needed to 
explore this potential therapeutic strategy.
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